AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03168074
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
Trial: NCT02236130
Drug: Local Anesthetic Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% Ropivacaine
Trial: NCT02236130
Drug: Opioids Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine
Trial: NCT00981786
Drug: Brimonidine/timolol fixed combination drops added to travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: twice daily administration
Trial: NCT00981786
Drug: Brinzolamide/timolol fixed combination drops added to travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: twice daily dosing
Trial: NCT01105650
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
Trial: NCT01105650
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
Trial: NCT01105650
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
Trial: NCT01105650
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
Trial: NCT01105650
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) 1 mg/kg Days -2 to +9
Trial: NCT01105650
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
Trial: NCT02281773
Drug: BI 409306 100 mg QD
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281773
Drug: BI 498306 50 mg QD
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281773
Drug: BI 498306 25 mg QD
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281773
Drug: BI 409306 10 mg QD
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219739
Drug: Imatinib mesylate 400 mg
RxNorm normalized name: Imatinib Mesylate 400 mg ORAL TABLET
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00219739
Drug: Imatinib mesylate 600 mg
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00219739
Drug: Imatinib 400 mg + Peg-Interferon
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00219739
Drug: Imatinib mesylate 400 mg + Cytarabine
RxNorm normalized name: imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04497935
Drug: PLENVU
RxNorm normalized name: Plenvu
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bowel preparation for a colonoscopy
Trial: NCT04497935
Drug: MoviPrep
RxNorm normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bowel preparation for a colonoscopy
Trial: NCT02162758
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole delayed-release capsules
Trial: NCT02162758
Drug: Dexlansoprazole Placebo
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules
Trial: NCT03336541
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Trial: NCT02513342
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d4 Docetaxel，75（mg/m2），iv；
Trial: NCT02513342
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d4，cisplatin，75（mg/m2），iv；
Trial: NCT00667407
Drug: Levalbuterol 1.25 mg
RxNorm normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days
Trial: NCT00667407
Drug: Racemic Albuterol Sulfate
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days
Trial: NCT00726375
Drug: Etanercept (Enbrel)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
Trial: NCT01364649
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine tablets
Trial: NCT00314171
Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the study eye(s) twice daily for 12 months
Trial: NCT00314171
Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the study eye(s) twice daily for 12 months
Trial: NCT02116803
Drug: dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
Trial: NCT02116803
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
Trial: NCT01364649
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram tablets
Trial: NCT01946165
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1,000 mg by mouth daily for each 28 day cycle.
Trial: NCT01946165
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg by mouth once daily for each 28 day cycle.
Trial: NCT01946165
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg by mouth daily for each 28 day cycle.
Trial: NCT01946165
Drug: LHRHa
RxNorm normalized name: ALARELIN ACETATE 800 ug in 1 mg INTRAMUSCULAR INJECTION, POWDER, FOR SUSPENSION [LHRHa]
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
Trial: NCT03243604
Drug: L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
Trial: NCT02114671
Drug: Faldaprevir high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral
Trial: NCT02114671
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, oral
Trial: NCT02114671
Drug: Faldaprevir low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral
Trial: NCT01437865
Drug: Gadofosveset contrast agent enhanced MRI Axilla
RxNorm normalized name: gadofosveset
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Trial: NCT01659567
Drug: Pegylated Interferon Alfa-2a
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
Trial: NCT01659567
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
Trial: NCT00181922
Drug: ziprasidone (Geodon)
RxNorm normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02946944
Drug: Sildenafil/apixaban
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Trial: NCT05701683
Drug: Lactobacillus Reuteri Probiotic
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
Trial: NCT02946944
Drug: apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Trial: NCT00329004
Drug: BMS-690514
RxNorm normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, up to 300 mg, once daily, up to 24 mos
Trial: NCT01011777
Drug: MDC
RxNorm normalized name: MDC
DrugBank: BK-MDA (DB12809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
Trial: NCT02277769
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Trial: NCT00918567
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open label treatment dosed up to 1.8mg/kg/day
Trial: NCT04615156
Drug: 18F-2-fluoro-2-deoxy-D-glucose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
Trial: NCT01536223
Drug: PF (cisplatin and 5-fluorouracil) group
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
Trial: NCT04198298
Drug: ProRoot MTA
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
Trial: NCT03932266
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
Trial: NCT03932266
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
Trial: NCT03932266
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
Trial: NCT00332761
Drug: Caduet
RxNorm normalized name: Caduet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01911975
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
Trial: NCT02799602
Drug: BAY1841788 / darolutamide (ODM-201)
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
Trial: NCT02799602
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by the treating physician.
Trial: NCT01000896
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous, 3 weeks
Trial: NCT01000896
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous, 3 weeks
Trial: NCT00162123
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Trial: NCT03792191
Drug: Intrathecal Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Trial: NCT00003706
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03966170
Drug: Citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline as neuroprotector
Trial: NCT03423082
Drug: 18F fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will receive one IV dose of 18F fluciclovine for PET scanning
Trial: NCT04591626
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT04591626
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT03051685
Drug: DFN-15 Dose 1
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03051685
Drug: DFN-15 Dose 2
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03051685
Drug: DFN-15 Dose 3
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03051685
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00661999
Drug: sodium ferric gluconate complex in sucrose
RxNorm normalized name: sodium ferric gluconate complex in sucrose 62.5 mg/5 mL INTRAVEN VIAL (ML)
DrugBank: Sodium ferric gluconate complex (DB09517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT00615784
Drug: Bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
Trial: NCT01434342
Drug: Nicotine Replacement Patch
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
Trial: NCT00234429
Drug: Gefitinib, raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02343120
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration by capsule